title: Potential Prognostic Molecular Signatures in a Preclinical Model of Melanoma.
abstract: Numerous studies have revealed a variety of pathways involved in the development of melanoma, however, the molecular and genetic divergence of underlying mechanisms remain vague. In a mouse model, we studied the expression pattern of insulin-like growth factor 2 mRNA-binding protein 1 (Igf2bp1) and target genes microphthalmia-associated transcription factor (Mitf), v-myc avian myelocytomatosis viral oncogene homolog (Myc), B-cell lymphoma 2 (Bcl2), prothymosin alpha (Ptma) and melan-A (Mlana) in relation to tumor-growth characteristics. The in vivo expression of the aforementioned genes was assessed by quantitative Real Time-Polymerase Chain Reaction (RT-PCR) in tumors established by B16-F1-derived clones. Gene expression was correlated with tumor growth characteristics. Simultaneous expression of elevated levels of Myc, Igf2bp1, Ptma and Mitf characterizes tumors with a more aggressive phenotype. Our findings introduce a tumor-specific molecular signature possibly associated with melanoma heterogeneity. The concomitant overexpression of key molecules such as IGF2BP1, PTMA, MYC and MITF could serve as prognostic or predictive marker.
authors.affiliation: Cancer Immunology and Immunotherapy Center, Saint Savvas Cancer Hospital, Athens, Greece.
authors.forename: Sotirios P
authors.initials: SP
authors.lastname: Fortis
authors.affiliation: Cancer Immunology and Immunotherapy Center, Saint Savvas Cancer Hospital, Athens, Greece.
authors.forename: Eleftheria A
authors.initials: EA
authors.lastname: Anastasopoulou
authors.affiliation: Cancer Immunology and Immunotherapy Center, Saint Savvas Cancer Hospital, Athens, Greece.
authors.forename: Ioannis F
authors.initials: IF
authors.lastname: Voutsas
authors.affiliation: Cancer Immunology and Immunotherapy Center, Saint Savvas Cancer Hospital, Athens, Greece.
authors.forename: Constantin N
authors.initials: CN
authors.lastname: Baxevanis
authors.affiliation: Cancer Immunology and Immunotherapy Center, Saint Savvas Cancer Hospital, Athens, Greece.
authors.forename: Sonia A
authors.initials: SA
authors.lastname: Perez
authors.affiliation: Cancer Immunology and Immunotherapy Center, Saint Savvas Cancer Hospital, Athens, Greece mahaira@ciic.gr.
authors.forename: Louisa G
authors.initials: LG
authors.lastname: Mahaira
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic; D005838:Genotype; D008546:Melanoma, Experimental / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D008810:Mice, Inbred C57BL; D051739:Microphthalmia-Associated Transcription Factor / Q000235:genetics / Q000378:metabolism; D010641:Phenotype; D011498:Protein Precursors / Q000235:genetics / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics / Q000378:metabolism; D016601:RNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012878:Skin Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D013947:Thymosin / Q000031:analogs & derivatives / Q000235:genetics / Q000378:metabolism; D013997:Time Factors; D047368:Tumor Burden
chemical_list: D014408:Biomarkers, Tumor; C519161:CRD-BP protein, mouse; D051739:Microphthalmia-Associated Transcription Factor; C497235:Mitf protein, mouse; C489428:Myc protein, mouse; D011498:Protein Precursors; D016271:Proto-Oncogene Proteins c-myc; D016601:RNA-Binding Proteins; C040782:prothymosin alpha; D013947:Thymosin
keywords: Igf2bp1; Melanoma; Ptma; molecular signatures; β-catenin/Wnt pathway